Abstract: A data processing method performed by a first device includes: generating, in response to first service data satisfying a data uploading condition, a first bit array corresponding to the first service data; encrypting the first bit array through a data key to obtain a ciphertext bit array, the data key being generated by a second device in a data intersection application run in a trusted execution environment of the second device; and transmitting the ciphertext bit array to a blockchain node for forwarding to a second device, for the second device to decrypt, in the data intersection application through the data key, the ciphertext bit array to obtain the first bit array.

Abstract: In a blockchain transaction execution method, a first transaction of a first blockchain is received from a proxy program component. The first transaction is based on a second transaction of a second blockchain. A data structure of the first transaction is different from a data structure of the second transaction. The second transaction is extracted from the first transaction. A virtual machine is invoked to execute the second transaction of the second blockchain. An execution result of the second transaction is transmitted to the application via the proxy program component.

Abstract: A blockchain-based data processing method, apparatus, and computer-readable medium are provided. Block proposal information is received including a block and a digital signature transmitted by an out-block node. The digital signature is obtained by performing digital signature processing on block header information included in the block. The block header information includes a first Merkel root determined based on transaction data in the block body information. Digest calculation on the block header information is performed to obtain first digest information. De-signature processing is performed on the digital signature to obtain second digest information. A second Merkel root is determined based on the transaction data acquired from the block proposal information when the first digest information and the second digest information are matched. An operation on the block is performed based on a comparison result of the first Merkel root and the second Merkel root.

Abstract: A multi-organ repairing and transferring device without interrupting a blood flow includes a first perfusion bin, a second perfusion bin and a third perfusion bin which are configured for storing respective organs. A first pump is arranged on a first pipeline, two ends of the first pipeline are connected with the first perfusion bin and the second perfusion bin respectively, a second pump is arranged on a second pipeline, two ends of the second pipeline are connected with the first perfusion bin and the second perfusion bin respectively, a third pump is arranged on a third pipeline, two ends of the third pipeline are connected with the first perfusion bin and the third perfusion bin respectively, and a fourth pump is arranged on a fourth pipeline, two ends of the fourth pipeline are connected with the first perfusion bin and the third perfusion bin respectively.

Abstract: A multi-organ repairing and transferring device without interrupting a blood flow includes a first perfusion bin, a second perfusion bin and a third perfusion bin which are configured for storing respective organs. A first pump is arranged on a first pipeline, two ends of the first pipeline are connected with the first perfusion bin and the second perfusion bin respectively, a second pump is arranged on a second pipeline, two ends of the second pipeline are connected with the first perfusion bin and the second perfusion bin respectively, a third pump is arranged on a third pipeline, two ends of the third pipeline are connected with the first perfusion bin and the third perfusion bin respectively, and a fourth pump is arranged on a fourth pipeline, two ends of the fourth pipeline are connected with the first perfusion bin and the third perfusion bin respectively.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: The present application provides an automatic knife stop device and a system for fibula cutting, a computer equipment, and a medium. The device includes: an acquisition module; a threshold module; and a judgment module. The present application can avoid the destruction of blood vessels during shaping and greatly improve the success rate of surgery, while greatly improve the robustness of the control system by increasing the strength of the force feedback signal.

Abstract: Disclosed is an ischaemia-free organ perfusion device and perfusion method. The perfusion device perfuses an isolated organ at normal temperature during whole transplantation, and comprises a first container, a second container, a first flow path, a second flow path, a third flow path and a fourth flow path. The perfusion device and the perfusion method are capable of maintaining the blood flow of the isolated organ during whole transplantation without interruption by machine perfusion, recovering the blood of the organ, effectively avoiding the interruption of blood supply for the organ during the whole transplantation, and improving the prognosis of organ transplantation.

Abstract: Disclosed are an in-vitro cardiopulmonary combined perfusion system and perfusion method. The in-vitro cardiopulmonary combined perfusion system includes an organ cabin, a circulation cabin, a control cabin, a simple breathing cabin, a display and control panel, and a base. The organ cabin is connected with the circulation cabin, the control cabin and the simple breathing cabin. The control cabin is connected with the display and control panel. The organ cabin, the circulation cabin, the control cabin, the simple breathing cabin, and the display and control panel are mounted on the base.

Abstract: Disclosed are an in-vitro cardiopulmonary combined perfusion system and perfusion method. The in-vitro cardiopulmonary combined perfusion system includes an organ cabin, a circulation cabin, a control cabin, a simple breathing cabin, a display and control panel, and a base. The organ cabin is connected with the circulation cabin, the control cabin and the simple breathing cabin. The control cabin is connected with the display and control panel. The organ cabin, the circulation cabin, the control cabin, the simple breathing cabin, and the display and control panel are mounted on the base.

Abstract: A 3D porous metal-organic framework and method of making are described. In some embodiments, a 3D porous metal-organic framework may be based on a trinodal (3,3,4) net of zyg topology by the self-assembly of the nonlinear hexacarboxylate (BHB) with the paddle-wheel Cu2(COO)4 cluster. Although its porosity and surface area are moderate, the open copper sites and optimal pore spaces enable the pore spaces to be fully utilized for methane storage, resulting in a high methane storage density and high absolute volumetric methane storage at room temperature and 35 bar. By the immobilization of high density open metal sites and the deliberate control of the pore space for their efficient methane storage, this porous MOF functions as an efficient media for methane and natural gas storage.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: A 3D porous metal-organic framework and method of making are described. In some embodiments, a 3D porous metal-organic framework may be based on a trinodal (3,3,4) net of zyg topology by the self-assembly of the nonlinear hexacarboxylate (BHB) with the paddle-wheel Cu2(COO)4 cluster. Although its porosity and surface area are moderate, the open copper sites and optimal pore spaces enable the pore spaces to be fully utilized for methane storage, resulting in a high methane storage density and high absolute volumetric methane storage at room temperature and 35 bar. By the immobilization of high density open metal sites and the deliberate control of the pore space for their efficient methane storage, this porous MOF functions as an efficient media for methane and natural gas storage.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.

Abstract: The present invention relates to a method of determining the genotype of a sample polynucleotide having at least a first variant site. At least a portion of the sample polynucleotide is amplified to obtain first amplicons, the first amplicons including the first variant site. The first amplicons are combined with first and second different polynucleotide controls, the first and second polynucleotide controls differing by at least one base therealong, the position of the at least one differing base corresponding to the first variant site of the sample polynucleotide. A plurality of first duplexes are prepared, each of at least some of the first duplexes comprising (i) a polynucleotide strand of one of the first amplicons and (ii) a complementary polynucleotide strand of the first polynucleotide control.

Abstract: The present invention relates to a method for determining the presence of a mutation in a first sample comprising first nucleotides. The reference sample comprising reference nucleotides. The first sample and a reference sample are subjected to electrophoresis in the presence of at least one intercalating dye. During electrophoresis the temperature of the first sample and the reference sample is changed by an amount sufficient to change an electrophoretic mobility of at least one of the first or reference nucleotides. Fluorescence intensity data are obtained. The fluorescence intensity data are indicative of the presence of the first and reference nucleotides. At least one of the first sample or reference samples comprises products resulting from a polymerase chain reaction (PCR), the products not having been desalted prior to electrophoresis.

Abstract: The present invention relates to a method for determining the presence of a mutation in a first sample comprising first polynucleotides. The reference sample comprises reference polynucleotides. The first sample and a reference sample are subjected to electrophoresis in the presence of at least one intercalating dye. During electrophoresis the temperature of the first sample and the reference sample is changed by an amount sufficient to change an electrophoretic mobility of at least one of the first or reference polynucleotides. Fluorescence intensity data are obtained. The fluorescence intensity data are indicative of the presence of the first and reference polynucleotides. The data are processed to determine the presence of mutation in the first polynucleotides.

Abstract: The present invention relates to a method of determining the genotype of a sample polynucleotide having at least a first variant site. At least a portion of the sample polynucleotide is amplified to obtain first amplicons, the first amplicons including the first variant site. The first amplicons are combined with first and second different polynucleotide controls, the first and second polynucleotide controls differing by at least one base therealong, the position of the at least one differing base corresponding to the first variant site of the sample polynucleotide. A plurality of first duplexes are prepared, each of at least some of the first duplexes comprising (i) a polynucleotide strand of one of the first amplicons and (ii) a complementary polynucleotide strand of the first polynucleotide control.